Real-world survival and prognostic factors in WHO 2021 classified gliomas treated with chemo-radiotherapy

The 2021 WHO glioma classification integrates molecular profiling, but outcome data for these patients are limited. We retrospectively analyzed 179 patients (median age 53) with WHO 2021-classified gliomas (grade 2: n = 45, grade 3: n = 51, grade 4: n = 83) treated with surgery and radio(chemo)thera...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Scientific reports Ročník 15; číslo 1; s. 38011 - 15
Hlavní autori:	Bilski, Mateusz, Noël, Georges, Smółka, Krzysztof, Kuncewicz, Katarzyna, Kuźnicki, Wojciech, Feuvret, Loic, Korab, Katarzyna, Peszyńska-Piorun, Magdalena, Korona, Paweł, Baranowska, Izabela, Suleja, Agata, Le Fevre, Clara, Schott, Roland, Somme, Laura, Chabli, Salma, Mesny, Emmanuel, Mastroleo, Federico, Kotecha, Rupesh, Jurkiewicz, Jakub, Fijuth, Jacek, Jereczek-Fossa, Barbara Alicja, Krystkiewicz, Kamil, Harat, Maciej, Kuncman, Łukasz
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 30.10.2025 Nature Publishing Group Nature Portfolio
Predmet:	631/67 692/4028 Adult Aged Brain cancer Brain Neoplasms - genetics Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - therapy Cell number Chemoradiotherapy - methods Chemotherapy Classification Clinical outcomes Female France Glioma Glioma - classification Glioma - genetics Glioma - mortality Glioma - pathology Glioma - therapy Humanities and Social Sciences Humans Isocitrate Dehydrogenase - genetics Leukopenia Lymphocytes Male Medical prognosis Middle Aged multidisciplinary Mutation Neoplasm Grading Poland Prognosis Radiation therapy Retrospective Studies Science Science (multidisciplinary) Steroids Survival Survival analysis Variables World Health Organization Young Adult Poland France
ISSN:	2045-2322, 2045-2322
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	The 2021 WHO glioma classification integrates molecular profiling, but outcome data for these patients are limited. We retrospectively analyzed 179 patients (median age 53) with WHO 2021-classified gliomas (grade 2: n = 45, grade 3: n = 51, grade 4: n = 83) treated with surgery and radio(chemo)therapy across four centers in Poland and France. Chemotherapy was administered to 74.9% of patients, with a median radiotherapy dose of 60 Gy (range 32.5–80 Gy). IDH1/2 mutations were identified in 55.3% and 1p/19q codeletion in 22.4%. Patients with IDH1/2 mutations had significantly longer progression-free survival (PFS, 7.7 vs. 1.0 years) and overall survival (OS, 8.2 vs. 2.5 years), both p < 0.01. 1p/19q codeletion was associated with prolonged PFS (7.7 vs. 1.6 years, p < 0.01). In grade 3 gliomas, chemotherapy improved PFS (6.8 vs. 3.6 years) and OS (6.9 vs. 3.9 years), both p < 0.01. Leukopenia grade 0–2 correlated with better PFS (3.6 vs. 1.2 years, p = 0.02) and OS (7.2 vs. 3.2 years, p = 0.04). Absolute lymphocyte count ≤ 1 × 10 3 /mm 3 predicted worse OS (5.3 vs. 8.7 years, p = 0.0043). CTV < 127 cm 3 predicted longer OS in grade 4 gliomas (3.2 vs. 1.7 years, p = 0.012). Our findings provide new real-world evidence on survival and prognostic factors in this population, for which contemporary RWE and OS/PFS data remain scarce.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-025-21934-2